Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data
Gyu Han Oh, Je-Chun Yu, Kyeong-Sook Choi, Eun-Jeong Joo, Seong-Hoon Jeong
Psychiatry Investig. 2015;12(1):46-54.   Published online 2014 Oct 1     DOI:
The Role of Antypsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia
A. A. Goncharova, E. G. Kornetova
Psychiatry.2020; 18(2): 32.     CrossRef
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients
Javier Vázquez-Bourgon, Miguel Ibáñez Alario, Jacqueline Mayoral-van Son, Marcos Gómez Revuelta, Rosa Ayesa Arriola, María Juncal Ruiz, Víctor Ortiz-García de la Foz, Benedicto Crespo Facorro
European Neuropsychopharmacology.2020; 39: 46.     CrossRef
Brexpiprazole: A Review in Schizophrenia
James E. Frampton
Drugs.2019; 79(2): 189.     CrossRef
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder
Catherine Weiss, Emmanuelle Weiller, Ross A. Baker, Ruth A. Duffy, Keva K. Gwin, Peter Zhang, Robert D. McQuade
International Clinical Psychopharmacology.2018; 33(5): 255.     CrossRef
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis
Yangyu Zhang, Yingyu Liu, Yingying Su, Yueyue You, Yue Ma, Guang Yang, Yan Song, Xinyu Liu, Mohan Wang, Lili Zhang, Changgui Kou
BMC Psychiatry.2017;[Epub]     CrossRef
In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery
Susanna Waters, Peder Svensson, Johan Kullingsjö, Henrik Pontén, Theresa Andreasson, Ylva Sunesson, Elisabeth Ljung, Clas Sonesson, Nicholas Waters
ACS Chemical Neuroscience.2017; 8(4): 785.     CrossRef
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
Pierre-Michel Llorca, Christophe Lançon, Ann Hartry, T. Michelle Brown, Dana B. DiBenedetti, Siddhesh A. Kamat, Clément François
BMC Psychiatry.2017;[Epub]     CrossRef
Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis
Zhihua Bai, Guoqiang Wang, Shangli Cai, Xindi Ding, Weiwei Liu, Depei Huang, Weidi Shen, Juncheng Zhang, Kui Chen, Yuqing Yang, Lili Zhang, Xiaochen Zhao, Qiong Ouyang, Jingping Zhao, Huafei Lu, Wei Hao
Schizophrenia Research.2017; 185: 73.     CrossRef
Antipsychotika-induzierte tardive Bewegungsstörungen – Fallbeispiel einer tardiven Dystonie unter Aripiprazol und Literaturübersicht
Martina Pitzer, Guido Engelmann, Thomas Stammschulte
Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie.2017; 45(4): 325.     CrossRef
Body mass index and blood glucose in psychiatric and general practice populations
Sarah McAvoy, Matthew Cordiner, Jackie Kelly, Laura Chiwanda, Christine Jefferies, Kirsteen Miller, Polash Shajahan
BJPsych Bulletin.2016; 40(3): 127.     CrossRef
The clinical challenges of akathisia
James B. Lohr, Carolyn A. Eidt, Areej Abdulrazzaq Alfaraj, Mounir A. Soliman
CNS Spectrums.2015; 20(S1): 1.     CrossRef
Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis
Fernanda S. Tonin, Thais Piazza, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
Schizophrenia Research.2015; 169(1-3): 483.     CrossRef